Immatics
- Country
- 🇩🇪Germany
- Ownership
- -
- Employees
- 343
- Market Cap
- $1.1B
- Introduction
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.
HonorHealth Launches First Global Trial of Novel T Cell Therapy Targeting Aggressive Melanoma
HonorHealth Research Institute has treated the first patient in a 50-site international Phase III clinical trial testing IMA203 TCR-T, the world's first T cell receptor therapy targeting PRAME in melanoma.
Immatics Announces Positive Clinical Data and Financial Update for Q3 2024
Immatics reported encouraging initial clinical data for TCER® IMA402 in melanoma, demonstrating favorable tolerability and early signs of dose-dependent anti-tumor activity.
Immatics' IMA203 Demonstrates Promising Efficacy and Safety in Melanoma Phase 1 Trial
Immatics' ACTengine IMA203 TCR-T therapy shows a confirmed objective response rate exceeding 50% in heavily pretreated melanoma patients.
Immatics' PRAME-Targeted Cell Therapy Shows Promise in Melanoma, Phase 3 Trial Planned
Immatics' IMA203, a T cell receptor-based therapy, demonstrated a confirmed response in over half of melanoma patients in an early-stage trial.
PRAME-Targeted T-Cell Therapy IMA203 Shows Promise in Metastatic Melanoma
IMA203, a PRAME-targeted T-cell therapy, demonstrated a 54% objective response rate in pretreated metastatic melanoma patients.
Novel Strategies Emerge to Transform 'Cold' Tumors into Immunotherapy-Responsive 'Hot' Tumors
Only 20% of cancers currently respond well to immunotherapy, with "hot" tumors like melanoma and lung cancer showing better outcomes than "cold" tumors such as pancreatic and brain cancers.